Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome
Katherine Drews‐Elger(University of Miami), Marc E. Lippman(Georgetown University), Toby M. Ward(Stanford University), Dafydd G. Thomas(University of Manchester), Adriana Campion‐Flora(Institute of Cancer Research), Jennifer Clarke(University of Nebraska–Lincoln), Elizabeth Iorns(Breast Cancer Now), Deborah L. Berry(Georgetown University), James M. Rae(University of Michigan), Jorge S. Reis‐Filho(AstraZeneca (France)), Daniel Nava Rodrigues(Institute of Cancer Research), Alexandra Dias(University of Miami), Philip Miller(University of California San Diego), Sonja Dean(University of Miami), Dorraya El‐Ashry(University of Miami)
Cited by 50
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
BiGG Models: A platform for integrating, standardizing and sharing genome-scale models
|Nucleic Acids Research|2015|1k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k